Sanofi and Lilly or follow GSK

After GlaxoSmithKline, Sanofi and Lilly, two of the world's top ten foreign pharmaceutical companies, were also investigated by the Shenyang industry and Commerce Department Taking GSK (GlaxoSmithKline) as the origin of the incident, in recent two weeks, AstraZeneca, Roche, Pfizer, Bayer and other pharmaceutical companies have been led into a long list of suspected investigations According to the latest news, Sanofi and Lilly, two of the top ten foreign pharmaceutical companies in the world, are also hard to escape Their China affairs have been investigated by Shenyang industry and Commerce Department Recently, Shenyang industry and Commerce conducted a temporary inspection on the sales and supplier system of Lilly company in China, and the rumor that a huge fine of 5 million yuan had been preliminarily drafted spread widely on the Internet Meanwhile, Sanofi and Roche were also investigated in Shenyang The news that the police plainclothes are suspected to be involved in the investigation directly reminds us of the case that GSK was put on file by the Ministry of public security A big storm may land soon According to Chen Wei, a person in the industry, there is a widespread saying that the national health authorities have decided to carry out a collective inspection from July 30 to August 3, specifically to thoroughly investigate the matter On July 31, Shanghai Health Bureau, procuratorate, Public Security Bureau, Shanghai Commission for Discipline Inspection and other departments were said to have carried out joint raids in Shanghai hospitals However, the major pharmaceutical companies that received the news of emergency response temporarily required the company to visit the medical representatives of the medical staff, and no sensitive materials (such as product materials, gifts, etc.) will be brought during the visit However, it is generally interpreted as a major event of expanding the scope of investigation and rectifying the industry of foreign pharmaceutical enterprises, but it has been reduced to routine inspection in succession among the enterprises suspected to be under investigation, just like falling into luoshengmen "Such inspections are carried out all year round and should not be linked to GSK events." Lilly China's Public Relations Department replied to reporters Abnormal surge of "routine investigation" Sanofi confirmed that Shenyang Administration for Industry and Commerce visited its Shenyang Office on July 29, but the purpose of the visit is not clear In the face of the rumor of being investigated, Lilly and Sanofi cannot remain silent at last Sanofi China confirmed the investigation in a statement in response to reporters "The company has learned that Shenyang Administration for Industry and Commerce visited Sanofi (China) Shenyang Office on July 29 The purpose of the visit is unclear As in other parts of the world, Sanofi also uses high standards of ethics in China to regulate our behavior and strictly abide by local laws and regulations " On the other hand, Lilly did not directly respond to the recent investigation and huge fines, but stressed that "this is a routine inspection by the competent government departments on the enterprises under their jurisdiction, which is totally different from the previous investigation led by the public security organs in the industry Shenyang Administration for Industry and Commerce conducted routine inspection on our business operation in early 2013 For these inspections, we always fully cooperate and follow up " It is worth noting that compared with the fact that many enterprises take turns to accept the investigation, the publication of the investigation results and punishment amount is particularly slow "In the end, the case determination, punishment and priority of the company are all the game and communication between the enterprise and the industrial and commercial department, and the government with stronger public relations ability tends to suffer less punishment In many cases, foreign companies will choose to take the initiative to "claim" part of the fine to cooperate with the regulatory authorities to avoid further serious incidents " A senior person from a large foreign pharmaceutical company told reporters In this person's view, ten days ago, the industrial and commercial department had covered a series of large companies in Shanghai, such as Novartis, AstraZeneca, Bayer and Roche Now, Lilly, Sanofi and other companies that came out were investigated collectively, which seems to be an industrial and commercial "sweeping" action These events do not necessarily have to be linked to GSK events, such actions are the usual behavior of the business sector all year round "Of course, it can't be ruled out that the local regulatory authorities think that by virtue of the impact of GSK events, we can vigorously carry out thorough investigation in the recent stage, which can more effectively combat commercial bribery and other violations." According to the person, usually the industry and Commerce Department will carry out "unannounced inspection" on key objects such as FMCG enterprises and pharmaceutical enterprises at the request of higher authorities or according to its own planning From administrative documents, sales account books to computer data, sometimes they even remove the computer directly and seal up the residual garbage "In case of any doubt, relevant personnel of the company will be taken away for questioning, which is the same as the nature of an AstraZeneca employee in Shanghai who was taken away last week." The medicine generation of the wind, the voice and the crane A number of medical representatives confirmed to reporters that a large number of investigators had been encountered during the recent visit to the hospital In the case of GSK, the medical representative, as the main operator of the actual bribery, was severely punished by the relevant departments Now, in order to make a breakthrough in the investigation, the relevant departments hope to conquer some drugs instead of obtaining the means of corporate bribery Coincidentally, Pfizer, which had previously insisted that it had not been investigated for this matter, also recently reported that sales representatives of tumor products were taken away for investigation In response, Pfizer's head of China's public relations department stressed to reporters that the incident was only a case of a doctor-patient dispute and had nothing to do with the expansion of GSK "In recent years, doctors have been advised to participate in as few activities sponsored by pharmaceutical companies as possible, and pharmaceutical representatives have also been restricted by rules and regulations in their regular visits, all of which are based on the principle of keeping a low profile when they are in the limelight." Chen Wei told reporters A number of medical representatives confirmed to the reporter that a large number of investigators had been encountered during the recent visit to the hospital, including those who ordered the temporary examination and those who investigated plain clothes They actively talked with the medical representatives about the sales situation of the antidote enterprises According to the rumor of five-day inspection by relevant departments, some large pharmaceutical companies have issued instructions to drug agents, and no doctor visit will be conducted during this period In terms of academic conferences sponsored by pharmaceutical companies, Sanofi and Roche were accused of suspending the national level marketing conference in the second half of the year in order to "cross the harbor safely" in a low-key way.